Figure 1: Schematic representation of mAbs development. This presentation is showing the evolutionary history of anti-CD20 mAbs development from ‘magic bullets’ concept to clinical reality against human lymphocytes. Moreover, the USA FDA approved antibodies are showing in green color whereas the India FDA approved antibody is showing in blue color.